BCM
ABUS icon

Bayesian Capital Management’s Arbutus Biopharma ABUS Stock Holding History

Bayesian Capital Management’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-12,100
Closed -$36K – 748
2022
Q1 		$36K Buy
+12,100
New +$37K 0.01% 738
2020
Q4 		– Sell
-20,600
Closed -$64K – 435
2020
Q3 		$64K Buy
+20,600
New +$62.7K 0.02% 491

Other funds holding ABUS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
FCM
FourWorld Capital Management New York $196M AUM 42.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bayesian Capital Management's ABUS Position: Q2 2022 in Review

Bayesian Capital Management sold out of Arbutus Biopharma (ABUS) in Q2 2022, closing a stake of 12,100 shares — an estimated $36K sold.

Bayesian Capital Management first reported a position in ABUS in Q3 2020 and held it in 2 quarters. The position peaked at $64K in Q3 2020. 113 funds tracked by Wall St. Rank hold ABUS as of Q2 2022.

  • Bayesian Capital Management reported no remaining Arbutus Biopharma position as of Q2 2022 after selling out during the quarter.
  • Bayesian Capital Management sold 12,100 Arbutus Biopharma shares in Q2 2022, an estimated $36K.
  • Bayesian Capital Management first reported a position in Arbutus Biopharma in Q3 2020 and held it in 2 quarters.
  • Bayesian Capital Management's Arbutus Biopharma position peaked at $64K in Q3 2020.
  • 113 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2022.

Based on Bayesian Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.